Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-11-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于公司被认定为2022年国家技术创新示范企业的自愿性披露公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by the company about being recognized as a '2022 National Technology Innovation Demonstration Enterprise' by the Ministry of Industry and Information Technology of China. It contains no financial statements, no detailed financial data, no management discussion of financial results, nor any regulatory filing or report publication. It is a regulatory announcement about a recognition or award, not a financial report or meeting material. The document length is short (945 characters), and it is an announcement of a status recognition, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2022-11-10 Chinese
关于取得两项医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of two medical device registration certificates issued by the National Medical Products Administration. It details product names, registration numbers, classifications, validity periods, and the impact on the company. The document is short (1548 characters) and serves as a formal disclosure of regulatory approval and its potential business impact. It does not contain financial statements, audit information, or detailed financial analysis. It is not a report or presentation but an official announcement of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-11-10 Chinese
关于高级管理人员购买公司房产暨关联交易的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding a related party transaction involving a senior management member purchasing company property. It details the transaction terms, approvals by the board and supervisory committee, and compliance with regulatory rules. It does not contain financial statements or quarterly/yearly financial results. It is not a report but an announcement of a specific corporate action related to management and related party transactions. This fits best under Board/Management Information (MANG) as it involves senior management and related party dealings, but since it is specifically about a related party transaction by senior management, and not a general board change announcement, it is still closest to MANG. The document length is short and focused on this transaction, not a full report or earnings release.
2022-11-01 Chinese
独立董事关于公司第四届董事会第四十三次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on a related party transaction involving senior management purchasing company property. It references regulatory guidelines and internal company rules but does not contain financial data, earnings, or report content. It is a governance-related document concerning board-level approval and oversight of transactions. It is not an announcement of a meeting, voting results, nor a financial report. Therefore, it fits best under Board/Management Information (MANG) as it relates to board-level management matters and approvals.
2022-11-01 Chinese
第四届监事会第四十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a supervisory board meeting resolution by the company 健帆生物科技集团股份有限公司. It details the meeting attendance, the agenda item discussed (approval of a related party transaction involving senior management purchasing company property), and the voting results. The document explicitly states it is a meeting resolution announcement and references a related announcement published on a regulatory disclosure website. The document length is short (707 characters), and it does not contain financial statements or detailed financial data. It is not an annual report, audit report, earnings release, or any detailed financial report. It is also not a proxy solicitation or voting results announcement for a shareholder meeting but a supervisory board meeting resolution. The closest fitting category is Regulatory Filings (RNS), as it is a regulatory announcement of a board/supervisory meeting resolution and related compliance information, but not a management change or AGM materials. Therefore, the classification is RNS with high confidence.
2022-11-01 Chinese
第四届董事会第四十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company 健帆生物科技集团股份有限公司. It details the convening of the fourth board meeting of the fourth session, attendance, and the approval of a specific agenda item related to a related-party transaction involving senior management purchasing company property. The document includes voting results and references compliance with company law and articles of association. There is no financial data or comprehensive report content, only a meeting resolution announcement. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document is short and focused on a board decision, not a full report or regulatory filing. Therefore, the classification is MANG with high confidence.
2022-11-01 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.